SynthesisDeutsches Arzteblatt international2023
Lung Cancer Screening With Low-Dose Computed Tomography.
Synthesis in Deutsches Arzteblatt international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- [Implementation of a national lung cancer screening in Austria : Position paper of the Austrian Radiological Society (ÖRG), the Austrian Society of Pneumology (ÖGP), the Austrian Society of General Practice and Family Medicine (ÖGAM) and the Austrian Society of Thoracic Surgery (ÖGTC)].Wiener klinische Wochenschrift · 2026Article
- AI-Driven Tumor Characterization and Histological Subtype Classification in Lung Cancer Using CT Imaging.Diagnostics (Basel, Switzerland) · 2026Article
- Quantitative CT analysis in lung cancer research: a bibliometric analysis based on Web of Science [2005-2025].Journal of thoracic disease · 2026Article
- Artificial intelligence-assisted early screening of lung cancer and accurate diagnosis of pulmonary nodules: research progress and clinical prospects from radiomics to multi-omics integration: a narrative review.Journal of thoracic disease · 2026Review
- Differential diagnosis of benign and malignant pulmonary nodules attached to the interlobar pleura.Quantitative imaging in medicine and surgery · 2026Article
- Preliminary reports of lung cancer screening with low-dose computed tomography: a nationwide performance on the Korean population in 2019-2020.European radiology · 2025Article
- Enhanced pulmonary nodule detection with U-Net, YOLOv8, and swin transformer.BMC medical imaging · 2025Article
- Updates on lung cancer screening for early detection.The Korean journal of internal medicine · 2025Review
- A novel composite model for distinguishing benign and malignant pulmonary nodules.Clinical and experimental medicine · 2025Article
- Non-small cell lung cancer in ever-smokers vs never-smokers.BMC medicine · 2025Article
- Clinical Value of Low-Dose Spiral CT Combined with Serum CEA in the Differential Diagnosis of Early Lung Cancer.Cancer management and research · 2025Article
- [Lung cancer screening: new frontiers].Radiologie (Heidelberg, Germany) · 2024Article
- Precision lung cancer screening from CT scans using a VGG16-based convolutional neural network.Frontiers in oncology · 2024Article
- Immaterial Conflicts of Interest Present.Deutsches Arzteblatt international · 2023Article
- In Reply.Deutsches Arzteblatt international · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 21 900 women and 35 300 men developed lung cancer in Germany in 2018, and 16 514 women and 28 365 men died of it. The outcome mainly depends on the tumor stage. In early stages (stage I or II), treatment can be curative; unfortunately, because early-stage lung cancers are generally asymptomatic, 74% of women and 77% of men already have advanced-stage disease (stage III or IV) at the time of diagnosis. Screening with low-dose computed tomography is an option enabling early diagnosis and curative treatment.
methodsThis review is based on pertinent articles retrieved by a selective search of the literature on screening for lung cancer.
resultsIn the studies of lung cancer screening that have been published to date, sensitivity ranged from 68.5% to 93.8%, and specificity from 73.4% to 99.2%. A meta-analysis by the German Federal Office for Radiation Protection revealed a 15% reduction in lung cancer mortality when low-dose computed tomography was used in persons who were judged to be at high risk for lung cancer (risk ratio [RR] 0.85, 95% confidence interval [0.77; 0.95]). 1.9% of subjects died in the screening arm of the metaanalysis, and 2.2% in the control group. The observation periods ranged from 6.6 to 10 years; false-positive rates ranged from 84.9% to 96.4%. Malignant findings were confirmed in 45% to 70% of the biopsies or resective procedures that were performed.
conclusionSystematic lung cancer screening with low-dose CT lowers mortality from lung cancer in (current or former) heavy smokers. This benefit must be weighed against the high rate of false-positive findings and overdiagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.